Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2017-11-29
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind placebo controlled study to evaluate safety and efficacy
of lucanthone administered as an adjunct to patients receiving whole brain radiation therapy
(WBRT) as primary treatment for brain metastases secondary to non-small cell lung cancer.